mTOR inhibitorFDA-approvedSecond-line
Everolimus
How it works
Blocks the mTOR pathway, which is involved in cell growth and division.
Cancer types
Breast Cancer— HER2-positive
Efficacy
Everolimus has been shown to improve progression-free survival in patients with HER2-positive metastatic breast cancer.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Everolimus Effectiveness in Rare Tumors Varies by Genetic Pathway | Pancreatic Cancer | observational | Alterations in the PI3K/AKT/mTOR pathway were associated with a higher disease control rate (85.7% vs. 28.6%); | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.